Investing.com - ARS Pharmaceuticals (NASDAQ: SPRY) reported second quarter EPS of $-0.13, $0.01 worse than the analyst estimate of $-0.12. Revenue for the quarter came in at $500K versus the consensus estimate of $1M.
ARS Pharmaceuticals's stock price closed at $9.78. It is up 11.90% in the last 3 months and up 39.71% in the last 12 months.
ARS Pharmaceuticals saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See ARS Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, ARS Pharmaceuticals's Financial Health score is "fair performance".
Check out ARS Pharmaceuticals's recent earnings performance, and ARS Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar